Aliga: Are Mergers Between Biology and Chemistry Financeable?

The combination of Dutch firm Kiadis and Germany's Biofrontera, a technological fit, now needs to score with investors and provide the proposed new firm with enough cash to survive the biotech drought.

Gerard Dijkstra, PhD, wants to grow familiar with the three hour drive between Leiden and Leverkusen. Today CEO of Kiadis Pharma Netherlands BV , Dijkstra aims to take the helm at Aliga Pharmaceuticals AG, the firm to be created by this first ever German-Dutch biotechnology merger. As Aliga's CEO, he'll likely spend quite a bit of time on the road between Kiadis' Leiden headquarters and the Leverkusen digs of the firm's merger partner, Biofrontera Pharmaceuticals GMBH[See Deal]—but only if the merger, which somewhat radically plans to keep both sites operating fully staffed, works.

Aliga will focus on developing drugs to treat pain and CNS disorders and operate as a holding company with two...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo